Growing cancer incidence and heightened focus on managing chemotherapy-related infections are driving global expansion in the febrile neutropenia treatment market, supported by biosimilar adoption and evolving clinical guidelines. https://www.datamintelligence.com/research-report/febrile-neutropenia-treatment-market